
Spectrum Pharmaceuticals SPPI
Spectrum Pharmaceuticals Total Liabilities | SPPI
Annual Total Liabilities Spectrum Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 75.4 M | 64 M | 62.6 M | 73 M | 119 M | 136 M | 193 M | 206 M | 235 M | 218 M | 216 M | 92.9 M | 89.2 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 235 M | 62.6 M | 137 M |
Quarterly Total Liabilities Spectrum Pharmaceuticals
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 80.9 M | 75.4 M | 83.1 M | 46 M | 44.8 M | 64 M | 68.3 M | 66.5 M | 56.6 M | 62.6 M | 69.6 M | 63.7 M | 62.2 M | 73 M | 59.1 M | 67.9 M | 80.1 M | 119 M | 126 M | 120 M | 120 M | 136 M | 197 M | 196 M | 186 M | 193 M | 199 M | 193 M | 193 M | 206 M | 233 M | 220 M | 238 M | 235 M | 253 M | 209 M | 209 M | 218 M | 151 M | 183 M | 202 M | 216 M | 230 M | 125 M | 94.4 M | 92.9 M | 92 M | 109 M | 92.9 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 253 M | 44.8 M | 137 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Chiasma, Inc.
CHMA
|
84.6 M | - | -6.00 % | $ 238 M | ||
|
vTv Therapeutics
VTVT
|
25.5 M | $ 16.0 | -2.2 % | $ 64.2 M | ||
|
Adamas Pharmaceuticals, Inc.
ADMS
|
170 M | - | - | $ 376 M | ||
|
Cellect Biotechnology Ltd.
APOP
|
6.48 M | - | 0.38 % | $ 12.9 M | ||
|
Xenon Pharmaceuticals
XENE
|
51.4 M | $ 36.89 | -1.78 % | $ 2.92 B | ||
|
Xeris Pharmaceuticals
XERS
|
370 M | $ 16.95 | 2.02 % | $ 2.72 B | ||
|
AzurRx BioPharma, Inc.
AZRX
|
15.6 K | - | 2.07 % | $ 34.4 M | ||
|
X4 Pharmaceuticals
XFOR
|
104 M | $ 3.01 | 1.69 % | $ 127 M | ||
|
Cerecor Inc.
CERC
|
19.2 M | - | -1.68 % | $ 283 M | ||
|
Constellation Pharmaceuticals, Inc.
CNST
|
31.1 M | - | - | $ 1.63 B | ||
|
Auris Medical Holding Ltd.
EARS
|
4.03 M | - | -1.77 % | $ 39.2 M | ||
|
Dicerna Pharmaceuticals, Inc.
DRNA
|
570 M | - | 0.34 % | $ 2.98 B | ||
|
ERYTECH Pharma S.A.
ERYP
|
53.9 M | - | 1.3 % | $ 27.7 M | ||
|
GW Pharmaceuticals plc
GWPH
|
198 M | - | - | $ 6.81 B | ||
|
22nd Century Group
XXII
|
8.53 M | $ 0.32 | -19.83 % | $ 58.9 K | ||
|
Kadmon Holdings, Inc.
KDMN
|
46.7 M | - | - | $ 1.7 B | ||
|
Liminal BioSciences
LMNL
|
14.3 M | - | - | $ 256 M | ||
|
argenx SE
ARGX
|
1.36 B | $ 926.42 | -1.66 % | $ 56.8 B | ||
|
Tonix Pharmaceuticals Holding Corp.
TNXP
|
32 M | $ 2.33 | -7.25 % | $ 19.8 M | ||
|
Zai Lab Limited
ZLAB
|
457 M | $ 21.01 | -4.16 % | $ 23 B | ||
|
Neos Therapeutics, Inc.
NEOS
|
97 M | - | -2.54 % | $ 57.2 M | ||
|
Zentalis Pharmaceuticals
ZNTL
|
72.8 M | $ 1.37 | 0.74 % | $ 98.5 M | ||
|
Zoetis
ZTS
|
12.1 B | $ 78.81 | -2.47 % | $ 34.9 B | ||
|
Odonate Therapeutics, Inc.
ODT
|
31.7 M | - | -3.18 % | $ 58.5 M | ||
|
Orphazyme A/S
ORPH
|
202 M | - | -2.25 % | $ 31.3 M | ||
|
Osmotica Pharmaceuticals plc
OSMT
|
277 M | - | -10.74 % | $ 89.9 M | ||
|
Pandion Therapeutics, Inc.
PAND
|
13.1 K | - | - | $ 1.77 B | ||
|
Xenetic Biosciences
XBIO
|
968 K | $ 1.47 | -4.55 % | $ 2.5 M | ||
|
Translate Bio, Inc.
TBIO
|
533 M | - | - | $ 2.81 B | ||
|
Trillium Therapeutics Inc.
TRIL
|
22 M | - | - | $ 1.94 B | ||
|
Urovant Sciences Ltd.
UROV
|
121 M | - | - | $ 532 M | ||
|
Acceleron Pharma Inc.
XLRN
|
77.2 M | - | - | $ 10.9 B | ||
|
Zogenix, Inc.
ZGNX
|
281 M | - | -4.97 % | $ 664 M | ||
|
Yunhong International
ZGYH
|
2.94 M | - | 0.10 % | $ 92.2 M | ||
|
ZIOPHARM Oncology, Inc.
ZIOP
|
22.4 M | - | -7.58 % | $ 264 M | ||
|
Taysha Gene Therapies
TSHA
|
96.4 M | $ 3.71 | -1.72 % | $ 1.19 B | ||
|
Vericel Corporation
VCEL
|
133 M | $ 57.41 | -1.46 % | $ 2.89 B | ||
|
Vir Biotechnology
VIR
|
238 M | $ 8.37 | -5.64 % | $ 1.16 B | ||
|
Veracyte
VCYT
|
96.4 M | $ 25.08 | 0.16 % | $ 1.97 B | ||
|
Viking Therapeutics
VKTX
|
76.7 M | $ 24.72 | -4.35 % | $ 2.79 B | ||
|
Vanda Pharmaceuticals
VNDA
|
162 M | $ 3.44 | -6.27 % | $ 203 M | ||
|
VistaGen Therapeutics
VTGN
|
13 M | $ 0.16 | -12.33 % | $ 6.09 M | ||
|
Voyager Therapeutics
VYGR
|
56.2 M | $ 1.52 | -5.9 % | $ 89.2 M | ||
|
Verrica Pharmaceuticals
VRCA
|
22.4 M | $ 2.74 | -5.03 % | $ 29.2 M | ||
|
Wave Life Sciences Ltd.
WVE
|
112 M | $ 2.56 | -6.07 % | $ 432 M | ||
|
XBiotech
XBIT
|
9.73 M | $ 1.75 | 4.17 % | $ 53.4 M | ||
|
XTL Biopharmaceuticals Ltd.
XTLB
|
5.84 M | $ 1.37 | -7.43 % | $ 922 M | ||
|
Adial Pharmaceuticals
ADIL
|
1.4 M | $ 3.15 | -35.42 % | $ 2.11 M | ||
|
ADMA Biologics
ADMA
|
147 M | $ 13.18 | -1.2 % | $ 3.14 B | ||
|
Exicure
XCUR
|
10.1 M | $ 0.96 | -7.24 % | $ 6.05 M |